São Paulo, June 25, 2024 – Eurofarma, a Brazilian-capital multinational operating in 22 countries and among the pharmaceutical companies with the highest investment in innovation, has just earned an important recognition from the Finance & Law Summit Awards (FILASA), 5th edition, in the category of Best Legal Department in the Pharmaceutical Industry. The award ceremony was held on June 18 at the WTC Convention Center in São Paulo.

The award is organized by Leaders League, an international ranking and business services agency (headquartered in Paris) focused on the Legal area, Private Equity and Financial Services, Human Capital, Innovation, Marketing, and Wealth Management.

“This is the first time we have received this recognition, and it is a great source of pride for the team, reinforcing how genuine our practices are and how much we believe they are fundamental values for the company,” comments Lizandra Lima, Legal Director at Eurofarma.

This year’s edition brought together more than 650 professionals and featured 23 panels with market leaders and experts addressing key current issues, such as the impact of data management on the financial sector, international fundraising by Brazilian companies, challenges for private equity investments, and the evolution of Brazilian entrepreneurship, among others.

The methodology used for the award was Leaders League’s impartial, comprehensive, and transparent research. In total, 32 companies were recognized across different categories. To learn more, visit: filasa.com.br/vencedores2024.

About Eurofarma

Founded in 1972, Eurofarma operates in the healthcare sector through the production and commercialization of products and services aimed at improving people’s quality of life. With a focus on generating shared value, the company covers the main pharmaceutical segments, such as prescription medicines, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, its portfolio includes more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.

A leader in medical prescriptions in Latin America and Brazil—where it holds the second position in generics—Eurofarma is present in 22 countries, with full coverage in Latin America and operations in the United States and Africa. The company has 12,600 employees and 11 manufacturing plants, with total production of 573 million units in 2023. In the same year, it invested more than R$ 680 million in innovation and achieved total net revenue of R$ 9.1 billion. Over the past 15 years, Eurofarma has recorded average annual growth of 17%.